MW 536.9 Da, Purity >97%. Carotenoid precursor of vitamin A. High-affinity antagonist for RARα, RARβ, and RARγ. Modulates intracellular redox status affecting redox-sensitive pathways involved in the regulation of cell cycle progression and apoptosis. Active in vivo and in vitro.
7235-40-7
> 97%
Solid
536.9 Da
C40H56
5280489
Synthetic
Liver-specific organic anion transporter 1, OATP-2, OATP-C, SLC21A6, SLCO1B1, SO1B1_HUMAN, Sodium-independent organic anion-transporting polypeptide 2, Solute carrier family 21 member 6, Solute carrier organic anion transporter family member 1B1
MW 536.9 Da, Purity >97%. Carotenoid precursor of vitamin A. High-affinity antagonist for RARα, RARβ, and RARγ. Modulates intracellular redox status affecting redox-sensitive pathways involved in the regulation of cell cycle progression and apoptosis. Active in vivo and in vitro.
Liver-specific organic anion transporter 1, OATP-2, OATP-C, SLC21A6, SLCO1B1, SO1B1_HUMAN, Sodium-independent organic anion-transporting polypeptide 2, Solute carrier family 21 member 6, Solute carrier organic anion transporter family member 1B1
7235-40-7
> 97%
Solid
536.9 Da
C40H56
5280489
Synthetic
Sol in benzene, chloroform, carbon disulfide; moderately sol in ether, petroleum ether, oils; 100 ml hexane dissolve 109 mg at 0 °C; very sparingly sol in methanol and ethanol; practically insol in water, acids, alkalies.
beta-Carotene
Carotenoid precursor of vitamin A. High-affinity antagonist for RARα, RARβ, and RARγ. Modulates intracellular redox status affecting redox-sensitive pathways involved in the regulation of cell cycle progression and apoptosis. Active in vivo and in vitro.
CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC=CC=C(C)C=CC=C(C)C=CC2=C(CCCC2(C)C)C)C)C
CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C/C=C/C=C(/C=C/C=C(/C=C/C2=C(CCCC2(C)C)C)\C)\C)/C)/C
InChI=1S/C40H56/c1-31(19-13-21-33(3)25-27-37-35(5)23-15-29-39(37,7)8)17-11-12-18-32(2)20-14-22-34(4)26-28-38-36(6)24-16-30-40(38,9)10/h11-14,17-22,25-28H,15-16,23-24,29-30H2,1-10H3/b12-11+,19-13+,20-14+,27-25+,28-26+,31-17+,32-18+,33-21+,34-22+
OENHQHLEOONYIE-JLTXGRSLSA-N
1,3,3-trimethyl-2-[(1E,3E,5E,7E,9E,11E,13E,15E,17E)-3,7,12,16-tetramethyl-18-(2,6,6-trimethylcyclohexen-1-yl)octadeca-1,3,5,7,9,11,13,15,17-nonaenyl]cyclohexene
Ambient - Can Ship with Ice
-20°C
Store under desiccating conditions, The product can be stored for up to 12 months
This supplementary information is collated from multiple sources and compiled automatically.
OATP1B1 also known as SLCO1B1 is a solute carrier organic anion transporter protein with a mass of approximately 85 kDa. This protein operates mechanically by transporting endogenous compounds and xenobiotics such as drugs across liver cell membranes. The primary expression of OATP1B1 occurs in the liver specifically on the basolateral membrane of hepatocytes. This localization facilitates its essential role in hepatic uptake of a variety of substances playing a critical role in pharmacokinetics.
OATP1B1 contributes prominently to drug metabolism and clearance. It actively transports diverse substrates including bile acids bilirubin and drugs such as statins. While not part of a larger complex OATP1B1 functions alongside other hepatic transporters to ensure efficient clearance and detoxification processes in the liver. The activity of OATP1B1 is fundamental for maintaining drug concentrations within therapeutic ranges thereby protecting against toxicity.
OATP1B1 is part of the hepatic drug metabolic pathway and the bile acid synthesis pathway. It works in coordination with other transporters like OATP1B3 and NTCP which also mediate hepatic uptake of organic anions and bile acids. The interaction among these transporters regulates the systemic levels of endogenous compounds and the clearance of therapeutic drugs influencing their efficacy and safety profiles.
OATP1B1 is linked to altered drug metabolism leading to statin-associated myopathy. Genetic variations in the OATP1B1 gene can reduce transporter function resulting in increased plasma concentration of statins which correlates with myopathy risk. Additionally OATP1B1 mutations may affect bilirubin handling contributing to conditions such as Rotor syndrome. Through these associations OATP1B1 interacts with other proteins affecting drug safety and disease states emphasizing its relevance in personalized medicine.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
2D chemical structure image of ab142849, beta-Carotene, Antioxidant
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com